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Abstract
Background: The aim of this study was to assess the prognostic accuracy of Child-Pugh and
APACHE II and III scoring systems in predicting short-term, hospital mortality of patients with liver
cirrhosis.
Methods: 200 admissions of 147 cirrhotic patients (44% viral-associated liver cirrhosis, 33%
alcoholic, 18.5% cryptogenic, 4.5% both viral and alcoholic) were studied prospectively. Clinical and
laboratory data conforming to the Child-Pugh, APACHE II and III scores were recorded on day 1
for all patients. Discrimination was evaluated using receiver operating characteristic (ROC) curves
and area under a ROC curve (AUC). Calibration was estimated using the Hosmer-Lemeshow
goodness-of-fit test.
Results:  Overall mortality was 11.5%. The mean Child-Pugh, APACHE II and III scores for
survivors were found to be significantly lower than those of nonsurvivors. Discrimination was
excellent for Child-Pugh (ROC AUC: 0.859) and APACHE III (ROC AUC: 0.816) scores, and
acceptable for APACHE II score (ROC AUC: 0.759). Although the Hosmer-Lemeshow statistic
revealed adequate goodness-of-fit for Child-Pugh score (P = 0.192), this was not the case for
APACHE II and III scores (P = 0.004 and 0.003 respectively)
Conclusion: Our results indicate that, of the three models, Child-Pugh score had the least
statistically significant discrepancy between predicted and observed mortality across the strata of
increasing predicting mortality. This supports the hypothesis that APACHE scores do not work
accurately outside ICU settings.
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Background
The recognition of risk factors that can stratify a popula-
tion of cirrhotic patients into subgroups with different
survival is of great prognostic value for the clinician. Nu-
merous attempts have been made to develop a reliable
prognostic survival model for cirrhosis. The target popula-
tion of the different scoring systems in the literature cov-
ers patients with liver cirrhosis [1–7], alcoholic liver
disease [8,9], variceal bleeding [10–17], and upper gas-
trointestinal bleeding including variceal bleeding [18–
20]. The Child-Turcotte classification [1] and its subse-
quent modification by Pugh [10] are old empiric methods
to assess hepatocellular functional reserve in candidates
for portosystemic shunting. Although Child-Turcotte and
Child-Pugh scores (CPS) have not been formally evaluat-
ed for their statistical accuracy, they have been useful for
risk-stratifying groups of patients with cirrhosis [21–23],
for assessing the efficacy of interventional procedures
such as transjugular intrahepatic portosystemic shunting
[24,25] or sclerotherapy [17,26], and for evaluating ther-
apy for complications of cirrhosis [27–29]. Although CPS
score is considered an adequate method to establish the
degree of liver failure and the survival probability [30],
two of its elements are very subjective (ascites and enceph-
alopathy), and a further limitation is its limited discrimi-
natory ability [7]. In some studies, the prognostic value of
CPS is described as incomplete, and other variables are
demonstrated to have prognostic significance [31]. In ad-
dition, prognostic factors unrelated to hepatic function
(cardiac, renal, pulmonary, acid-base and electrolyte sta-
tus, other important associated comorbid conditions and
factors) are not included.
Acute Physiology, Age and Chronic Health Evaluation
(APACHE) II and III scores were developed by Knaus et al
in 1985 and 1991, respectively [32,33] are being used
mainly for critically ill patients of all disease categories ad-
mitted to the intensive care units (ICUs). They differ in
how chronic health status is assessed, in the number of
physiologic variables included (12 vs. 17), and in the total
score. Specific parameters of liver function (i.e. serum bi-
lirubin and albumin) are included only in the APACHE III
scoring system. Some prognostic variables (e.g., pro-
thrombin time) and other indicators of responses to ther-
apy (e.g., blood units transfused) which are known to be
important outcome predictors in cirrhotic patients are not
measured by the acute physiology scores [17,21,22,26].
APACHE II and III scores have been successfully used to
risk stratify cirrhotic patients admitted to medical ICUs
[34–38]. APACHE II has been previously used to risk strat-
ify a mixed population of both ICU and non-ICU cirrhotic
patients with upper gastrointestinal bleeding [39], while
recently, an incomplete APACHE III score (i.e. a score in
which data for blood gas analysis were omitted) has been
reported to be superior to CPS in risk stratifying cirrhotic
patients outside ICU settings [40].
The aim of the present study was to compare the prognos-
tic accuracy of Child-Pugh, 24 hour APACHE II and com-
plete 24 hour APACHE III scoring systems in predicting
hospital mortality of patients with liver cirrhosis admitted
to a gastroenterological medical ward.
Methods
This prospective study included two hundred consecutive
hospitalizations of 147 patients with liver cirrhosis admit-
ted to the Department of Gastroenterology of the Univer-
sity Hospital of Heraklion, from February 1999 through
January 2001. For the purpose of the study, each admis-
sion was considered as one patient. The criterion for inclu-
sion was the presence at admission or in the past history
of any of the major complications of cirrhosis (ascites, en-
cephalopathy, variceal bleeding or spontaneous bacterial
peritonitis). Patients transferred from elsewhere were in-
cluded in the study only if the transfer occurred within 24
hours after initial admission. Patients with hepatocellular
carcinoma and patients admitted for less than one day
were excluded. Patients admitted to a medical ICU during
the first 24 hours of their presentation were also excluded.
The diagnosis of cirrhosis was based on liver biopsy in 93
out of 200 patient admissions (46.5%). For the remaining
107 patient admissions, the diagnosis of cirrhosis was
based on clinical, laboratory and radiological criteria: his-
tory of portal hypertension excluding other etiologies, ev-
idence of esophageal varices confirmed by endoscopy,
splenomegaly, ascites confirmed by abdominal ultra-
sound and physical examination, impaired liver function
tests and clotting profile, ultrasound or computer tomog-
raphy criteria [39,41].
To calculate the APACHE II score [32], twelve common
physiological and laboratory values (temperature, mean
arterial pressure, heart rate, respiratory rate, oxygenation
(PaO2 or A-aDo2), arterial pH, serum sodium, serum po-
tassium, serum creatinine, haematocrit, white blood cell
count and Glasgow coma score) are marked from 0 to 4,
with 0 being the normal, and 4 being the most abnormal.
The sum of these values is added to a mark adjusting for
patient age and a mark adjusting for chronic health prob-
lems (severe organ insufficiency or immunocompromised
patients) to arrive at the APACHE II score.
APACHE III scores range from 0 to 299 and are derived
from marks for the extent of abnormality of 17 physiolog-
ic measurements (the acute physiology score), adjusts for
age, and adjusts for seven comorbidities that reduce im-
mune function and influence hospital survival [33]. The
17 physiological variables include eleven laboratory pa-
rameters (haematocrit, white blood cell count, serumBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/7
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creatinine, serum BUN, serum sodium, serum albumin,
serum bilirubin, blood glucose, PaO2, A-aDO2, and a
scoring for acid-base abnormalities), five vital signs
(pulse, mean blood pressure, temperature, respiratory
rate, urine output) and a modified Glasgow coma score.
Clinical and laboratory data necessary to the CPS and
APACHE systems and prothrombin time (PT) values were
recorded on the first day for all patients. Physiological
data (temperature, heart rate, mean blood pressure and
respiratory rate) were recorded 3-hourly during the first
24 hours of admission. The calculation of APACHE II and
III scores was based on the worst values taken during the
first 24 hours after admission.
Statistical analysis
Chi-square test was used to assess the differences of mor-
tality within Child-Pugh classes A, B, and C. Individual re-
lationship of each score (CPS, APACHE II, APACHE III)
and PT values to the risk of death was assessed by t-test.
For the assessment of the magnitude of correlation of
length of stay (LOS) with CPS, APACHE II and APACHE
III, Pearson correlation was used. Descriptive statistics
were expressed as mean ± SD unless otherwise stated. Dis-
crimination was tested using the receiver operating char-
acteristic (ROC) curves and by comparing areas under the
curve (AUCs) [42]. AUCs between 0.7 and 0.8 were classi-
fied as "acceptable" and between 0.8 and 0.9 as "excel-
lent" discrimination [43]. For the different scoring
systems tested, the sensitivity, specificity, overall correct-
ness of prediction, positive and negative predictive values
were calculated, and the cutoff point giving the best
Youden index was determined [44]. This cutoff point was
also used to calculate the predicted and observed outcome
for patients. In order to test the overall classification accu-
racy of APACHE III score in association with PT, we ap-
plied discriminant analysis (backward stepwise method).
A P value less than 0.05 was considered statistically signif-
icant for all above analyses. Calibration was assessed us-
ing the Hosmer-Lemeshow goodness of fit statistic which
divides subjects into deciles based on predicted probabil-
ities of death and then computes a chi-square from ob-
served and expected frequencies [45]. Lower chi-square
values and higher P values are associated with a better fit.
A good fit was defined as P > 0.05.
Results
Of the 200 patient admissions, 137 (68.5%) were men
and 63 were women. The mean age was 62.3 years (range,
33–86 years). Eighty eight (44%) admissions were for vi-
ral-associated cirrhosis (HBV-associated 40 cases, HCV-as-
sociated 48 cases), 66 (33%) for alcoholic cirrhosis and 37
(18.5%) for cryptogenic cirrhosis. In 9 cases (4.5%) there
was both viral and alcoholic etiology. The reasons for ad-
mission were ascites for 127 patients (63.5%), encepha-
lopathy for 37 (18.5%), variceal bleeding for 54 (27%),
spontaneous bacterial peritonitis for eight (4%), and an-
other infection (respiratory, biliary and urinary tract infec-
tions, cellulitis) for 36 patients (18%). Five cases were
transferred to a medical ICU. During this study period, 23
patients (11.5%) died. Three patients died in the ICU and
20 patients in the medical ward. The causes of death were
liver failure in seven cases (30.4%), kidney failure in two
cases (8.7%), hepatorenal syndrome in seven cases
(30.4%), variceal bleeding in one case (4.5%), and infec-
tion in six cases (26%).
Forty nine cases (24.5%) were classified as Child-Pugh
class A, 88 cases (44%) as class B and 63 cases (31.5%) as
class C. No deaths were recorded among patients with
Child-Pugh class A. Two patients with Child-Pugh class B
and 21 with class C died. Mortality increased significantly
with increasing Child-pugh classes (P < 0.001). Table 1
shows that there were significant differences in CPS,
APACHE II score, APACHE III score, and PT between sur-
vivors and non-survivors. Table 2 reports predictive values
of the various scoring systems calculated at the cutoff
point giving the best Youden index. ROC curves are
shown in Figure 1. Discrimination power of CPS AUC and
APACHE III AUC was excellent, while that of APACHE II
AUC was acceptable. When information regarding PT val-
ues were combined with APACHE III score into a new dis-
criminant function, the overall classification accuracy of
APACHE III was not improved, thus PT was deleted from
the full model (non-significant at the 5% level). The re-
sults of Hosmer-Lemeshow goodness-of-fit tests are
shown in Table 3, while deciles risk are shown in Tables 4,
5 and 6. The Hosmer-Lemeshow statistic was best for CPS.
However, for the two APACHE scores, calibration was
poor.
The median LOS for survivors was 9 days (range 2–85
days), 7 days (range 2–17 days) for patients with Child-
Pugh class A, 9 days (range 2–48 days) for Class B, and 15
days (range 2–85 days) for those with class C. CPS and
APACHE III score correlated strongly with the duration of
hospitalization (P < 0.001), while APACHE II score had a
weak and non significant correlation.
Discussion
The performance of the prognostic models is evaluated by
their discrimination and calibration. Discrimination (i.e
the ability of a prognostic score to classify patients correct-
ly as survivors or non-survivors) is measured by AUC
[42,43]. Calibration evaluates the degree of correspond-
ence between the estimated probabilities of mortality pro-
duced by a model and the actual mortality experience of
patients and can be tested using Hosmer-Lemeshow good-
ness-of-fit statistic [45].BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/7
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In our series, discrimination was acceptable to excellent
for Child-Pugh and APACHE scores, however both
APACHE prognostic systems had inadequate goodness-of-
fit for death. Our results for APACHE II and CPS discrim-
ination compare well with those published by Afessa et al
[39]. In their study, the prognostic value of APACHE II
(AUC 0.78) was as good as that of Child-Pugh score (AUC
0.76) in predicting short-term outcome of 111 cirrhotic
patients hospitalized for upper gastrointestinal bleeding,
although no informations regarding correct classification
rates, sensitivity, specificity, cutoff values and goodness-
of-fit have been assessed. The reported APACHE II mean
Figure 1
ROC curves for CPS, APACHE II and APACHE III scoring systems
Table 1: Average values on prothrombin time and average scores on Child-Pugh, APACHE II and APACHE III
Survivors (N = 177) Nonsurvivors (N = 23) P value
Child-Pugh score 8.05 ± 2.24 11.13 ± 1.60 < 0.001
APACHE II score 11.45 ± 3.86 15.73 ± 5.24 < 0.001
APACHE III score 41.67 ± 15.13 66.04 ± 21.46 < 0.001
Prothrombin time* 16.95 ± 3.45 21.20 ± 5.15 < 0.001
All data reported as mean ± SD All data were recorded during the first 24 hours after admission to the ward N = number of patients *in seconds
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values were higher for both survivors and non-survivors
(17.2 ± 6 and 25.6 ± 10.1 respectively). However, 71% of
their patients were ICU admissions and 57.6% had active
variceal bleeding, thus they have studied much sicker pa-
tients than those included in our sample.
Butt et al reported that by using discriminant analysis,
APACHE III score correctly classified 75% of cases vs. 67%
of cases for Child-Pugh score [40]. No cutoff values were
reported, the overall model calibration was not tested and
data from blood gas analysis were not included in the cal-
culation of the APACHE III score, thus resulting in an in-
complete score. The APACHE III mean values were found
high for both survivors and non-survivors (58.9 ± 35.1
and 87.4 ± 30.3 respectively). This might be related to the
high percentage of patients admitted with upper gastroin-
testinal tract bleeding (i.e. 57%). Since four out of five vi-
tal signs (pulse, mean blood pressure, respiratory rate, and
possibly urine output) and some of the laboratory param-
eters (i.e. haematocrit, serum BUN, and possibly creati-
nine) which need to arrive at the APACHE III score are
markedly affected by bleeding, this might be the reason of
the observed higher scores. Furthermore, the authors did
not specify if they have included patients admitted to a
medical ICU during the first 24 hours of their admission,
whereas patients with hepatocellular carcinoma were also
included in the study. The reported mortality on day 1 was
26% and 68% in patients with an APACHE III score of 51
to 75 points and greater than 75 respectively. It is note-
worthy that in our series 17 out of 67 patients (25.3%)
with an APACHE III score of 51 to 75 and 6 out of 11 pa-
tients (54.5%) with an APACHE III score greater than 75
also died. This suggests that at least in this sub-group of
sicker patients our results compare well.
There are many potential reasons for insufficient calibra-
tion of APACHE scores. Clinically useful predictive mod-
els should demonstrate ease of use, accuracy,
reproducibility and acceptance by data collecting stuff
[46]. Some variables of the APACHE scores (i.e heart rate)
depend on continuous monitoring. In addition, it has
been shown that the inter-observer variability is high
when these scoring systems are not used on a regular basis
(like in most non-ICU wards), thus affecting the accuracy
and reproducibility of the data [47,48]. This is potentially
relevant in our study, since physiological data collection
was performed by several physicians and over a long peri-
od of time (24 months). As previously suggested [49] we
tried to minimize variability by having one person to co-
ordinate the process of data collection and having a
written reference of definitions based on the original arti-
cles of APACHE scores.
Another potential reason for the inadequate calibration is
the differences in level of disease severity between our da-
tabase and the development databases of the mortality
prediction systems [50]. Statistically derived prediction
models like the APACHE systems are calibrated to the
Table 2: Comparison of the predictive values of the scoring systems
Parameter Child-Pugh APACHE II APACHE III
Cutoff pointa 10 15 62
Youden index 0.67 0.43 0.63
Sensitivity (%) 91 65 73
Specificity (%) 76 77 89
Correct classification (%) 78 76 87
Positive predictive value (%) 33 27 47
Negative predictive value (%) 98 94 96
AUC (95% CI)b 0.859 0.759 0.816
(0.793 to 0.924) (0.704 to 0.928) (0.634 to 0.882)
aValue giving the best Youden index bAUC; area under the curve
Table 3: Hosmer-Lemeshow goodness-of-fit tests
Chi-Square DF P value
Child-Pugh score 8.693 6 0.192
APACHE II score 19.157 6 0.004
APACHE III score 23.622 8 0.003BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/7
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overall outcome prevalence in the development sample.
Although APACHE II and III have been shown to work
well in cirrhotic patients with a high severity of illness ad-
mitted to ICUs [34–38], it is a well known fact that the
mortality prediction models performance usually deterio-
rates when models are applied to different population
samples (i.e. less sick patients) [51]. In studies conducted
in cirrhotic patients admitted to ICU, cutoff values for
APACHE II have ranged from 17 (AUC O.69; ICU mortal-
ity rate 52%) to 22 (AUC 0.79; ICU mortality rate 36%,
hospital mortality 46%) [34,37], while those reported for
APACHE III have ranged from 75 (AUC 0.78; ICU mortal-
ity rate 43%, hospital mortality 57%) to 80 (AUC 0.75)
[34,35]. In our series, APACHE II scores equal or greater
than 17 and 22, and APACHE III scores equal or greater
than 75 and 80 were recorded in only 25 (12.5%), 5
Table 4: Tables of deciles risk for Child-Pugh score
Decile N PD AD PS AS
12 8 0 . 2 02 7 . 8 2 8
22 1 0 . 3 02 0 . 7 2 1
33 1 0 . 7 13 0 . 3 3 0
42 5 1 . 1 02 3 . 9 2 5
53 2 2 . 5 12 9 . 5 3 1
62 3 3 . 2 71 9 . 8 1 6
72 8 8 . 7 91 9 . 3 1 9
8 12 6.5 5 5.5 7
N = number of patients; PD = predicted to die; AD = actually died; PS = predicted to survive; AS = actually survived
Table 5: Tables of deciles risk for APACHE II score
Decile N PD AD PS AS
12 2 0 . 3 22 1 . 7 2 0
22 0 0 . 5 11 9 . 5 1 9
32 1 0 . 9 02 0 . 1 2 1
42 4 1 . 5 02 2 . 5 2 4
54 7 4 . 3 44 2 . 7 4 3
63 7 5 . 5 53 1 . 5 3 2
72 4 7 . 2 61 6 . 8 1 8
852 . 9 52 . 1 0
N = number of patients; PD = predicted to die; AD = actually died; PS = predicted to survive; AS = actually survived
Table 6: Tables of deciles risk for APACHE III score
Decile N PD AD PS AS
12 0 0 . 2 01 9 . 8 2 0
22 2 0 . 4 12 1 . 6 2 1
32 2 0 . 6 02 1 . 4 2 2
42 6 0 . 9 42 5 . 1 2 2
52 2 1 . 0 02 1 . 0 2 2
62 1 1 . 5 11 9 . 5 2 0
72 0 2 . 4 01 7 . 6 2 0
82 1 4 . 3 21 6 . 7 1 9
9 20 7.5 12 12.5 8
10 6 4.2 3 1.8 3
N = number of patients; PD = predicted to die; AD = actually died; PS = predicted to survive; AS = actually survivedBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/7
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(2.5%), 11 (5.5%) and 8 (4 %) patients respectively, thus
emphasizing the much lower level of disease severity in
our patients. It should be also recognized that the wide
95% CI of our AUCs (Table 2) suggests sample size prob-
lem, especially when only 23 patients died.
Potential limitations of our study should also be men-
tioned. Our study was performed in an academic referral
hospital; therefore our results may not be applicable to in-
stitutions with different patient populations. Because
mathematical equations for APACHE III have not been
published and for APACHE II this equation is available
only for admission, these equations have not been used to
calculate the relative risk of death. In agreement with oth-
er studies [34,35,37,39,40], we wanted to test the accuracy
of single-score values. Patients admitted to a medical ICU
during the first 24 hours of their presentation were exclud-
ed from our study, thus resulting in a mortality rate of
only 11.5%. It could be stated that the rational of exclud-
ing these patients weakens our study, since sicker patients
at presentation are more likely to die. However, physio-
logical data included in APACHE III score are recorded 3-
hourly during the first 24 hours of admission and the
worst value at this time interval is taking into account to
calculate the total score [33]. Furthermore, we aimed to
define within a 24 hour interval patients not sick enough
to be admitted in a medical ICU, but who are likely not to
benefit from the standard therapy and for whom a more
intensive monitoring and treatment might be tried.
Conclusions
In conclusion, we cannot recommend the use of APACHE
II and III scores in non-ICU patients. The present study
showed that the discrimination power of CPS AUC and
APACHE III AUC was excellent, while that of APACHE II
AUC was acceptable. Although the Hosmer-Lemeshow
statistic revealed adequate goodness-of-fit for CPS, this
was not the case for APACHE II and III scores. Our results
indicate that between the three scores, CPS had the least
statistically significant discrepancy between predicted and
observed mortality across the strata of increasing predict-
ing mortality. This supports the hypothesis that APACHE
scores do not work accurately outside ICU settings.
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